# Impli

> Impli is a London and Switzerland-based medtech company building implantable and skin-worn biosensors that read reproductive hormones in real time and stream them to a phone. Its first market is IVF, where patients currently endure near-daily blood draws and clinicians dose powerful drugs off readings that can be a day or two out of date. Founded in 2019 by CEO Anna-Luisa Schaffgotsch and built on 15 years of Imperial College London biosensor research, Impli has drawn a Bayer partnership, a £1.4m NIHR grant, and a 2027 launch target.

- **Founded:** 2019
- **Headquarters:** London, United Kingdom
- **Founders:** Anna-Luisa Schaffgotsch (CEO & Founder)
- **Team size:** 14
- **Products:** ImpliCaspian, Impli Ceres, BEAM (Bio-Endocrine Analysis Monitor)
- **Notable:** Released ImpliCaspian, described as the first subdermal NFC medical-information implant of its kind., Won a Bayer innovation challenge at HLTH Europe (Amsterdam) and secured a Bayer R&D partnership (October 2024)., Awarded a £1.4m NIHR Invention for Innovation grant (June 2026) for a 30-month clinical programme.

## Products & services

- **ImpliCaspian** — The company's first product: a rice-sized subdermal NFC implant that stores a person's medical information under the skin and is read by tapping an NFC-enabled smartphone. Insertion takes about two minutes with a two-day healing window.
- **Impli Ceres** — An implantable, rice-grain-sized electrochemical biosensor that continuously monitors reproductive hormone levels in the interstitial fluid between cells and transmits readings wirelessly to a smartphone.
- **BEAM (Bio-Endocrine Analysis Monitor)** — A microneedle skin patch worn on the upper arm that continuously measures three fertility hormones - oestradiol, luteinising hormone and progesterone - and streams data to a phone, where AI software converts it into real-time hormone trends.

## Achievements

- Released ImpliCaspian, described as the first subdermal NFC medical-information implant of its kind.
- Won a Bayer innovation challenge at HLTH Europe (Amsterdam) and secured a Bayer R&D partnership (October 2024).
- Awarded a £1.4m NIHR Invention for Innovation grant (June 2026) for a 30-month clinical programme.
- Selected as a Venture Leaders Medtech / Venturelab company.
- Named among FemTech startups to watch for 2026.

## Latest updates

- **2026-07** — Featured in coverage of continuous hormone monitoring alongside Clue founder Ida Tin, who is backing the category.
- **2026-06** — Awarded £1.4m NIHR i4i grant to run a 30-month, 25-patient first-in-human trial of the BEAM microneedle biosensor with Imperial College Healthcare NHS Trust and King's College London.
- **2026-01** — Recorded a debt financing round of roughly $90,000.
- **2024-10** — Announced strategic R&D partnership with Bayer after winning a Bayer innovation challenge at HLTH Europe in Amsterdam.

## Links

- Website: https://impli.co
- LinkedIn: https://www.linkedin.com/company/impli
- Twitter/X: https://twitter.com/Impli11
- Instagram: https://www.instagram.com/impliworld/
- Facebook: https://www.facebook.com/Impliworld/

---

Profile page: https://yespress.io/impli
Published by YesPress — https://yespress.io
Last updated: 2026-08-21